4588 Oncolys BioPharma Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4588

TSE Growth

Oncolys BioPharma Inc.

923

JPY

-31

(-3.25%)

Dec 5, 3:30 pm JST

5.97

USD

Dec 5, 1:30 am EST

Result

ー

PTS

outside of trading hours

914

Dec 5, 11:58 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	642	-1,454	-1,500	-1,615	-95.5	0	Feb 10, 2022	J-GAAP
Dec, 2022	976	-1,204	-1,163	-1,148	-66.3	0	Feb 10, 2023	J-GAAP
Dec, 2023	63	-1,929	-1,913	-1,938	-108.9	0	Feb 9, 2024	J-GAAP
Dec, 2024	31	-1,681	-1,663	-1,684	-77.2	0	Feb 7, 2025	J-GAAP
Dec, 2025 Guidance	ー	ー	ー	ー	－	0	Feb 7, 2025	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2020	Feb 7, 2020	ー	ー	ー	ー	0	J-GAAP
- - - - Results	Feb 12, 2021	314	-1,674	-1,723	-2,095	0	J-GAAP
Dec, 2021	Feb 12, 2021	Available in future release
	Jan 24, 2022
Results	Feb 10, 2022
Dec, 2022	Feb 10, 2022
Results	Feb 10, 2023
Dec, 2023	Feb 10, 2023
	Dec 15, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024
Results	Feb 7, 2025
Dec, 2025	Feb 7, 2025	ー	ー	ー	ー	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2008	254	－	Available in future release
Dec, 2009	67	-73.6
Dec, 2010	266	+297.0
Dec, 2011	185	-30.5
Dec, 2012	396	+114.1
Dec, 2013	1	-99.7
Dec, 2014	28	+2,700.0
Dec, 2015	121	+332.1
Dec, 2016	178	+47.1
Dec, 2017	229	+28.7
Dec, 2018	168	-26.6
Dec, 2019	1,303	+675.6
Dec, 2020	314	-75.9
Dec, 2021	642	+104.5
Dec, 2022	976	+52.0
Dec, 2023	63	-93.5
Dec, 2024	31	-50.8
Dec, 2025 Guidance	ー	-100.0	ー	+100.0	ー	+100.0	－	+100.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	63	-1,929	-3,062	-107.37	-82.64	0.03	-108.9
Dec, 2024	31	-1,681	-5,423	-80.13	-64.30	0.01	-77.2
Dec, 2025 Guidance	ー	ー	ー	ー	ー	ー	－

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,303	-140	28	37	854.8
Fiscal Year	Dec, 2019	Dec, 2012	Dec, 2010	Dec, 2010	Dec, 2010

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	550	-546	-573	-578	-33.4	0	Feb 10, 2023	J-GAAP
Jul - Dec, 2023	0	-1,029	-1,046	-1,070	-60.1	0	Feb 9, 2024	J-GAAP
Jul - Dec, 2024	0	-888	-911	-930	-42.6	0	Feb 7, 2025	J-GAAP
Jul - Dec, 2025 Guidance	ー	ー	ー	ー	－	0	Feb 7, 2025	J-GAAP
YoY	－	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	-1,204	-1,697	-1,717	20	-113	1,466	55.32	J-GAAP
Dec, 2023	-1,929	-1,341	-1,336	-5	1,142	1,287	63.09	J-GAAP
Dec, 2024	-1,681	-2,024	-2,020	-4	2,879	2,165	67.70	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	63	-1,311	-1,270	-1,272	-73.2	ー	Nov 10, 2023	J-GAAP
Jan - Sep, 2024	31	-1,230	-1,243	-1,246	-59.6	ー	Nov 8, 2024	J-GAAP
Jan - Sep, 2025	28	-1,571	-1,614	-1,617	-64.6	ー	Nov 7, 2025	J-GAAP
YoY	-9.7%	-27.7%	-29.8%	-29.8%	-8.5%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	0	-618	-643	-666	-37.4	-Inf	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	0	-378	-363	-364	-18.2	-Inf	May 10, 2024	J-GAAP
Apr - Jun, 2024	31	-415	-389	-390	-19.1	-1,338.7	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	0	-437	-491	-492	-23.5	-Inf	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	0	-451	-420	-438	-20.1	-Inf	Feb 7, 2025	J-GAAP
Jan - Mar, 2025	0	-785	-810	-811	-32.7	-Inf	May 9, 2025	J-GAAP
Apr - Jun, 2025	28	-482	-501	-502	-20.2	-1,721.4	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	0	-304	-303	-304	-12.2	-Inf	Nov 7, 2025	J-GAAP
YoY	－	+30.4%	+38.3%	+38.2%	+48.3%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	107	-83.9	Available in future release
Jan - Mar, 2021	62	-11.4
Apr - Jun, 2021	131	+98.5
Jul - Sep, 2021	125	+76.1
Oct - Dec, 2021	324	+202.8
Jan - Mar, 2022	193	+211.3
Apr - Jun, 2022	233	+77.9
Jul - Sep, 2022	358	+186.4
Oct - Dec, 2022	192	-40.7
Jan - Mar, 2023	35	-81.9
Apr - Jun, 2023	28	-88.0
Jul - Sep, 2023	0	-100.0
Oct - Dec, 2023	0	-100.0
Jan - Mar, 2024	0	-100.0
Apr - Jun, 2024	31	+10.7
Jul - Sep, 2024	0	－
Oct - Dec, 2024	0	－
Jan - Mar, 2025	0	－
Apr - Jun, 2025	28	-9.7
Jul - Sep, 2025	0	－	-304	+30.4	-303	+38.3	-12.2	+48.1

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	663	89	88	87	6.4
Fiscal Year	Dec, 2019	Jun, 2019	Jun, 2019	Jun, 2019	Jun, 2019

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2022	124.20	81.2	2,650	2,151	-1,434	0.18	Feb 10, 2023	J-GAAP
Dec, 2023	74.35	71.5	2,040	1,459	-3,373	0.21	Feb 9, 2024	J-GAAP
Dec, 2024	110.40	85.8	3,198	2,744	-5,057	0.12	Feb 7, 2025	J-GAAP
Jan - Sep, 2025	ー	79.1	2,188	1,731	-1,617	0.19	Nov 7, 2025	J-GAAP

Oncolys BioPharma Inc.(4588) Financial Results